Data use:

We use cookies and similar tools to make your use of this website easy and to keep it working properly. We may share data about you and how you use the site with third parties, such as analytics and marketing partners. Learn more in our Privacy Policy and Terms of Use. By continuing to use the site, you agree to this.

Site Logo

for Business

Farxiga® (dapagliflozin), Xigduo® XR (dapagliflozin/metformin) – Expanded indication

June 12, 2024 - AstraZeneca announced the FDA approval of Farxiga (dapagliflozin) and Xigduo XR (dapagliflozin/metformin), as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.

Download PDF

RxNews®

Farxiga® (dapagliflozin), Xigduo® XR (dapagliflozin/metformin) – Expanded indication